GeneDx Holdings Corp.
WGSHealthcareNASDAQDiagnostics & Research · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 27
Part of the healthcare sector, GeneDx Holdings Corp. (WGS) is listed under Diagnostics & Research. The $1.43B market capitalization puts WGS squarely in small-cap range for its industry. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Market Cap
$1.43B
Beta
2.07
P/E (TTM)
—
P/E (Fwd)
39.16
EPS (TTM)
$-2.66
EPS (Fwd)
$1.23
ROE
-30.4%
ROA
-4.4%
Cash
$170.7M
Total Debt
$168.2M
Free CF
$3.6M
52W Change
-31.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $170.7M in cash comfortably exceeding the $168.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $3.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -30.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $234.7M (2022) to $427.5M (2025), reflecting a 82% increase over the period.
GeneDx Holdings Corp.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GeneDx Holdings Corp.'s trajectory.